Skip to content
DraconiticResearch
Search Sources API
190,860 studies31 sourcesUpdated 13 min ago
Peer-reviewedCC BYJournal of the American Heart Association

Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction

  • Padmini Selvaganesan1,2
  • Mohamad Karnib1,2
  • Irfan Helmy1,2
  • Rosita Zakeri3
  • Yusef Babar Saeed2,4,5
  • Jayakumar Sahadevan1,2
  • Mohammed Najeeb Osman1,2,4
  • Anirban Mondal6
  • Sherry Milfred‐LaForest2
  • James C. Fang7
  • Yogesh N.V. Reddy8
  • Varun Sundaram1,2,4,9
9 affiliations
  1. 1Case Western Reserve University School of Medicine
  2. 2Louis Stokes Cleveland Veterans Affairs Medical Center
  3. 3King's College London
  4. 4Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center
  5. 5Geriatric Research, Education and Clinical Center (GRECC), Louis Stokes Cleveland VA Medical Center
  6. 6Case Western Reserve University
  7. 7University of Utah
  8. 8Mayo Clinic
  9. 9University Hospitals Research and Education Institute
Read full textDOICite

Abstract

Background To evaluate whether GLP‐1 (glucagon‐like peptide‐1) receptor agonists (GLP‐1RAs), compared with DPP4 (dipeptidyl peptidase‐4) inhibitors or sulfonylureas, are associated with reduced all‐cause mortality or heart failure hospitalizations in patients with obesity and type 2 diabetes, and heart failure with preserved ejection fraction. Methods PRAISE‐HFpEF (Glucagon‐Like Peptide‐1 Receptor Agonist in Obese Heart Failure With Preserved Ejection Fraction) was a nationwide multicenter cohort study using a new‐user, active‐comparator design within the national Veterans Affairs Health System (170 US hospitals). Adults with type 2 diabetes between January 1, 2000 and December 31, 2021, were identified from centralized electronic health records. Patients with heart failure with preserved ejection fraction and a body mass index ≥30 kg/m2 were selected using a validated diagnostic algorithm. Exposure was initiation of a GLP‐1RA versus DPP4 inhibitors/sulfonylurea from January 1, 2015 to December 31, 2021. The primary outcome was time to all‐cause mortality or heart failure hospitalization. Inverse probability of treatment weighting based on the propensity score was used to balanced baseline characteristics. Results Among 179 288 patients with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, 1024 GLP‐1RA users and 796 DPP4 inhibitors/sulfonylurea users met inclusion criteria. Over a median follow‐up of 1.5 years, GLP‐1RA use was associated with a lower risk of the primary outcome (adjusted hazard ratio, 0.78 [95% CI, 0.64–0.95], P=0.01). Weight loss was modestly greater with GLP‐1RAs compared with DPP4 inhibitors/sulfonylurea (−12.9% versus −10.1%). Conclusions Among patients with obese heart failure with preserved ejection fraction and type 2 diabetes, GLP‐1RA initiation was associated with a lower incidence of death or heart failure hospitalization compared with alternative oral agents.

Related

  1. Glucagon-like peptide-1 receptor agonists in diabetic patients with heart failure with reduced ejection fraction - real world outcomes
    Y. Hammer, Y. J. Cohen, R. Arbel +6
    medRxivPreprintCC BY-NC-NDFull textCardiovascular medicinemedRxiv
  2. Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists
    M. Al-Nusair, A. Maini, S. Khurana +1
    medRxivPreprintCC BYFull textCardiovascular medicinemedRxiv
  3. Angiotensin receptor neprilysin inhibitor (ARNI) in right ventricular failure and preserved LV ejection fraction: A systematic review and meta-analysis.
    Mohsen Safari, Zeinab Safari
    Caspian journal of internal medicinePeer-reviewedCC BY-NCFull textCardiovascular medicineEurope PMC
  4. Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention
    Alaa Solaiman Algazzar
    Saudi Journal of Internal MedicinePeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismDOAJ
  5. Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework
    Huili Li, Shengke Peng, Daoxi Lei
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{selvaganesan2026glucagonlike,
  title = {{Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction}},
  author = {Padmini Selvaganesan and Mohamad Karnib and Irfan Helmy and Rosita Zakeri and Yusef Babar Saeed and Jayakumar Sahadevan and Mohammed Najeeb Osman and Anirban Mondal and Sherry Milfred‐LaForest and James C. Fang and Yogesh N.V. Reddy and Varun Sundaram},
  journal = {Journal of the American Heart Association},
  year = {2026},
  month = oct,
  doi = {10.1161/jaha.126.050387},
  url = {https://www.ahajournals.org/doi/10.1161/JAHA.126.050387},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction
AU  - Padmini Selvaganesan
AU  - Mohamad Karnib
AU  - Irfan Helmy
AU  - Rosita Zakeri
AU  - Yusef Babar Saeed
AU  - Jayakumar Sahadevan
AU  - Mohammed Najeeb Osman
AU  - Anirban Mondal
AU  - Sherry Milfred‐LaForest
AU  - James C. Fang
AU  - Yogesh N.V. Reddy
AU  - Varun Sundaram
PY  - 2026
DA  - 2026/10/30
JO  - Journal of the American Heart Association
DO  - 10.1161/jaha.126.050387
UR  - https://www.ahajournals.org/doi/10.1161/JAHA.126.050387
AB  - Background To evaluate whether GLP‐1 (glucagon‐like peptide‐1) receptor agonists (GLP‐1RAs), compared with DPP4 (dipeptidyl peptidase‐4) inhibitors or sulfonylureas, are associated with reduced all‐cause mortality or heart failure hospitalizations in patients with obesity and type 2 diabetes, and heart failure with preserved ejection fraction. Methods PRAISE‐HFpEF (Glucagon‐Like Peptide‐1 Receptor Agonist in Obese Heart Failure With Preserved Ejection Fraction) was a nationwide multicenter cohort study using a new‐user, active‐comparator design within the national Veterans Affairs Health System (170 US hospitals). Adults with type 2 diabetes between January 1, 2000 and December 31, 2021, were identified from centralized electronic health records. Patients with heart failure with preserved ejection fraction and a body mass index ≥30 kg/m2 were selected using a validated diagnostic algorithm. Exposure was initiation of a GLP‐1RA versus DPP4 inhibitors/sulfonylurea from January 1, 2015 to December 31, 2021. The primary outcome was time to all‐cause mortality or heart failure hospitalization. Inverse probability of treatment weighting based on the propensity score was used to balanced baseline characteristics. Results Among 179 288 patients with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, 1024 GLP‐1RA users and 796 DPP4 inhibitors/sulfonylurea users met inclusion criteria. Over a median follow‐up of 1.5 years, GLP‐1RA use was associated with a lower risk of the primary outcome (adjusted hazard ratio, 0.78 [95% CI, 0.64–0.95], P=0.01). Weight loss was modestly greater with GLP‐1RAs compared with DPP4 inhibitors/sulfonylurea (−12.9% versus −10.1%). Conclusions Among patients with obese heart failure with preserved ejection fraction and type 2 diabetes, GLP‐1RA initiation was associated with a lower incidence of death or heart failure hospitalization compared with alternative oral agents.
SN  - 2047-9980
ER  -